Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research

Recruiting now · Not applicable

Conditions studied: Colorectal Cancer, Liver Metastases, Genetic Change

In brief

The patients with non-resectable colorectal liver metastases (CRLM) have always being considered a particular subgroup of CRLM in which the therapeutic approach, is focused on strategies that allow a potential surgery like neoadjuvant systemic treatments. But, the underlying biology that causes this particular profile of spread in a proportion of patients that always recur and progress in the liver has not been properly characterized from a biological point of view. Unfortunately, these patients finally develop liver metastasis not amenable for local treatments and become refractory to systemic treatments even without developing extrahepatic liver metastases. As a result, liver transplantation (LT) is a potential for patients without extrahepatic involvement and nonresectable CRLM. There are several studies that aims to evaluate if LT increases overall survival compared to best alternative care. To our knowledge, none of these studies incorporate objectives focused on the underlying tumor biology of this particular population and the development of focused strategies including a dynamic disease monitoring and targeted treatments for this particular population.The METLIVER trial will permit to expand the genetic studies to the whole complexity of metastatic lesions and a more precise evaluation of their genetic heterogeneity. Moreover, it will help to precise the type of genetic analyses on liquid biopsies that can be designed for patients that will unfortunately relapse mostly with lung metastases after LT. Our proposal will maximize the opportunity to produce an unprecedented knowledge on CRLM evolution and will provide new opportunities for relapsed patients.

Key facts

Study ID

NCT05398380

Run by

Hospital Vall d'Hebron

People needed

35

Starts

2022-01-01

Expected to finish

2026-12-31

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide written informed consent.
• Male or female, aged 18-70 years old inclusive at study entry.
• ECOG (Eastern Cooperative Oncology Group) 0 or 1.
• Histologically-proven primary colorectal tumor.
• Bilateral, limited at liver and non-resectable CRLM by consensus in Multidisciplinary Committee.
• Resection of primary colorectal tumor according oncological principles and adequate TNM stage.
• Time from primary colorectal tumor resection to transplant ≥ 12 months.
• Primary colorectal tumor stage ≤ T3N1. If time between primary tumor resection is ≥ 2 years, stage T4N0 or T4N2 is accepted.
• No signs of extrahepatic metastatic disease according to PET/CT scan, CT and pelvic MRI.
• The patient has undergone systemic chemotherapy for a minimum of 3 months at the time of screening and maximum of 2 lines of fluoropyrimidine based chemotherapy combined or not with irinotecan or oxaliplatin associated or no not with targeted therapy based in molecular biomarkers.
• Demonstrated stability or partial regression of CRLM following RECIST criteria v 1.1., at minimum 3 months since the last treatment received and immediately prior to screening.
• CEA (Carcinoembryonic antigen) values ≤ 80 µg/L immediately prior to screening.
• Adequate blood test regarding:
• Creatinine ≤1.25 x upper normal level or estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2 using following the Chronic Kidney disease epidemiology collaboration (CKD-EPI) formula.
• Platelets ≥80 × 109/L
• Neutrophiles ≥ 2.5 × 109/L
• Patients with hepatic failure after resection will be considered if it occurs as a consequence of an inadequate preoperative estimation of the functional volume that would have contraindicated the surgery. They should meet the inclusion criteria and none of the exclusion criteria.

You may not qualify if…

• Largest Lesion >5.5cm immediately prior to screening
• Patients with Lynch Syndrome
• BRAF mutation and/or primary tumor of microsatellite instability (MSI)
• Recurrence of primary tumor confirmed by colonoscopy or pelvic MRI within the last 12 months prior to screening.
• Previous or concurrent cancer in the last 5 years. Any cancer curatively treated 5 years prior to entry or treated basal cell carcinoma is permitted.
• Substance abuse, medical, psychological or social conditions that may interfere with the patient´s participation in the study or evaluation of the study results.
• Cardiac or pulmonary disease uncontrolled as contraindication for any surgical procedure.
• Active infection.
• Pregnant or breast-feeding patients
• Any reason why in the opinion of the investigator, the patient should not participate.

Where it is running

• Department of HPB Surgery and Transplants, Hospital Vall d´Hebron — Barcelona, Barcelona, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.